New Hopes for Patients With Testicular Cancer

Testicular cancer has a 5-year survival rate of about 95 percent.

Current diagnosis heavily relies on invasive biopsies.

The microRNA-371∼373 cluster shows promise as a non-invasive diagnostic tool.

Limitations exist in current biomarkers used for diagnosis.

Early recurrence detection is possible with new testing methods.

There is ongoing research to solve 'the teratoma challenge.'

Centralization of testing is recommended for better accuracy.

Further studies on epigenetics could lead to new treatments.